Rapid Cellular Fibronectin Assay for Bleeding Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current assays for detecting cellular fibronectin in human blood plasma are too time-consuming and ineffective for clinical use, particularly in predicting bleeding events, as they are limited to a small range of concentrations and require specialized training, making them unsuitable for rapid and accurate measurement of high c-Fn levels associated with increased bleeding risk.
Innovation Solution
A rapid assay using antibodies specific to synthetic polypeptides that can detect cellular fibronectin over its entire range of interest, allowing for quantitative measurement in less than 20 minutes without specialized training, utilizing a sandwich or competitive format with paramagnetic particles and a 'one-touch' point-of-care instrument.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of time
If current assays for detecting cellular fibronectin are used, then detection capability is achieved, but the assay time is too long and requires specialized training
Solution Approach 1:
The assay is segmented into discrete, pre-prepared components including coated paramagnetic particles, antibody solutions, and substrate solutions. Each component is independently optimized and can be prepared in advance, eliminating the need for complex manual preparation and reducing assay time while making the procedure easier to perform.
Solution Approach 2:
Antibodies are pre-coated onto paramagnetic particles and stored as ready-to-use reagents. This preliminary preparation eliminates time-consuming coating steps during actual assay performance and reduces the technical skill required, as the complex antibody coating process has already been completed during manufacturing.
2Adaptability or versatility
If current assays are used to detect cellular fibronectin, then detection is possible, but they are limited to a small range of concentrations
Solution Approach 1:
The assay utilizes a competitive binding format where the signal response changes non-linearly with analyte concentration, creating an inverted U-shaped curve. By measuring at multiple time points and using appropriate mathematical transformations, the assay achieves precise quantification across a wide concentration range from low to high c-Fn levels, overcoming the limitation of traditional assays that are only linear in a small range.
3Productivity
If rapid detection is implemented, then assay time is reduced, but measurement accuracy and reliability may be compromised
Solution Approach 1:
The assay employs continuous incubation and binding processes without interruption, allowing the reaction to proceed to completion in a shortened time frame. The competitive binding mechanism ensures that equilibrium is reached rapidly and maintained, enabling accurate measurements to be obtained within 20 minutes without sacrificing reliability.
Solution Approach 2:
The assay replaces complex mechanical separation and washing steps with magnetic field-based separation using paramagnetic particles. This substitution allows for rapid, automated manipulation of reagents while maintaining precise control over binding conditions, thereby preserving measurement reliability while reducing assay time.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables rapid, accurate, and quantitative measurement of cellular fibronectin levels, facilitating timely clinical decisions for predicting bleeding events in cardiovascular and neurological conditions, allowing for point-of-care testing and minimizing the risk of fatal bleeding side effects.
Implementation Method 1
A rapid assay using antibodies specific to synthetic polypeptides that can detect cellular fibronectin over its entire range of interest
Implementation Method 2
utilizing a sandwich or competitive format with paramagnetic particles
Data Source
AI summary
The present invention relates to a rapid assay for detection of human cellular fibronectin (c-Fn) where ELISA-based assays have previously been developed for detecting and measuring cellular fibronectin in biological fluids, but these methods are too time-consuming for practical clinical diagnostic use. The assay of the present invention enables prediction of bleeding events on a rapid timescale. Described as well are high affinity human monoclonal antibodies, particularly those directed against isotopic determinants of cellular fibronectin (c-Fn), as well as direct equivalents and derivatives of these antibodies. These antibodies bind to their respective target with an affinity at least 100 fold greater than they do to plasma fibronectin, and enable assays to be created that detect c-Fn in less than 30 minutes in a variety of detection formats, and in some detection formats less than 15 minutes. These antibodies are useful for diagnostics, particularly prediction of bleeding events, prophylaxis and treatment of disease.